ACTG

Business Context and Reporting Period

Company: Acacia Research Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 1998
Business Model: A diversified company making direct investments in and providing management services to emerging businesses, primarily in technology and biotechnology sectors. The company operates through seven key enterprises, including CombiMatrix (biotech), Soundview Technologies (telecommunications), and Acacia Capital Management (investment advisory).

Key Financial Metrics

Note: Revenue is derived almost exclusively from capital management fees ($382,000). Operating expenses include significant amortization of patents and goodwill ($1,568,000) and increased R&D costs ($1,880,000).

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased by 22% to $382,000, driven by lower performance fees from investment funds due to lower returns generated by fund activities.
• Expense Surge: Operating expenses increased 59% to $6.2 million. Key drivers included:
  • Amortization of patents and goodwill rising to $1.57 million (vs. $459,000 in 1997) following acquisitions of majority interests in Soundview Technologies and increased stakes in other affiliates.
  • Research and Development expenses doubling to $1.88 million, primarily due to CombiMatrix's expanded efforts.
  • Increased headcount and general administrative costs.
• Liquidity Improvement: Cash and cash equivalents increased significantly to $7.5 million, bolstered by $8.5 million in proceeds from the sale of common stock and $3.7 million from the exercise of stock options and warrants.
• Debt: The company incurred $1.22 million in long-term indebtedness, primarily related to notes issued by subsidiary CombiMatrix.

Outlook, Risks, and Management Commentary

• Outlook: Management anticipates that existing working capital reserves will cover operating expenses for at least the next twelve months without major new investments. However, the company intends to seek additional financing for new or existing businesses, which may be dilutive.
• Year 2000 Compliance: The company is in the remediation phase of its Year 2000 compliance plan. Estimated total costs are not expected to be material (less than $10,000 future costs), but risks remain regarding third-party dependencies (e.g., data lines, utilities).
• Risks:
  • Venture Capital Risk: High risk of loss associated with investments in start-ups with unproven technologies (e.g., CombiMatrix, Signature-mail.com). Most affiliates have incurred consistent operating losses and generated no or minimal revenue.
  • Intellectual Property: Success depends heavily on patent validity and enforcement. Pending litigation regarding Soundview Technologies' V-chip patent was settled in October 1998, but future challenges remain a risk.
  • Liquidity of Investments: Significant portions of assets are tied up in private partnerships and affiliates with no public market, creating liquidity constraints.
• Unusual Items: In 1997, a $460,000 legal settlement expense was recorded. In 1998, a $101,000 write-down of promissory notes secured by Whitewing Labs stock was recorded.

Investor Verification Checklist

• Revenue Sustainability: Verify the stability of capital management fees, which constitute 100% of operating revenue, and their dependence on fund performance.
• Amortization Impact: Confirm the duration and magnitude of future amortization charges related to the Soundview Technologies acquisition and other intangible assets.
• Affiliate Viability: Assess the progress of key affiliates (CombiMatrix, Signature-mail.com, MerkWerks) toward commercialization, as they currently generate no revenue and rely on continued funding.
• Cash Burn Rate: Monitor the rate of cash consumption against the $7.5 million cash balance to determine the runway before additional financing is required.
• Patent Litigation: Review the status of Soundview Technologies' V-chip patent enforcement and potential future challenges to its validity.